Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
730.5 CHF | +2.38% | +6.18% | +7.27% |
25/04 | EMS-Chemie Q1 Net Sales Decline | MT |
14/02 | Bank Vontobel Lowers Price Target on EMS-Chemie, Maintains Hold Recommendation | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 37.48 and 33.88 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.27% | 18.68B | C+ | ||
+11.47% | 63.22B | A- | ||
-3.47% | 46.34B | A- | ||
+13.72% | 39.97B | B+ | ||
+17.83% | 25.46B | A- | ||
-0.57% | 17.24B | B+ | ||
-21.73% | 15.81B | A- | ||
+0.22% | 14.9B | B+ | ||
-19.10% | 13.74B | C+ | ||
+35.12% | 12.81B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMSN Stock
- Ratings EMS-CHEMIE HOLDING AG